Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.

@article{Kim2007EffectsOO,
  title={Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.},
  author={Dennis Y Kim and Leigh A Macconell and Dongliang Zhuang and Prajakti A. Kothare and Michael E. Trautmann and Mark S Fineman and Kristin Taylor},
  journal={Diabetes care},
  year={2007},
  volume={30 6},
  pages={
          1487-93
        }
}
OBJECTIVE In patients with type 2 diabetes, exenatide reduces A1C, postprandial and fasting glucose, and weight. In this study we investigated the effects of continuous exenatide administration from a long-acting release (LAR) formulation. RESEARCH DESIGN AND METHODS In this randomized, placebo-controlled phase 2 study, exenatide LAR (0.8 or 2.0 mg) was administered subcutaneously once weekly for 15 weeks to subjects with type 2 diabetes (n = 45) suboptimally controlled with metformin (60… CONTINUE READING
1
Twitter Mention

Citations

Publications citing this paper.
SHOWING 1-10 OF 15 CITATIONS

Injectable formulations of poly(lactic acid) and its copolymers in clinical use.

  • Advanced drug delivery reviews
  • 2016
VIEW 2 EXCERPTS
CITES BACKGROUND

Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential.

  • Obesity reviews : an official journal of the International Association for the Study of Obesity
  • 2011
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 31 REFERENCES

Exenatide maintained glycemic control with associated weight reduction over three years in patients with type 2 diabetes (Abstract)

JB Buse, L MacConell, +6 authors DD Kim
  • Diabetes 56 (Suppl
  • 2007
VIEW 1 EXCERPT

Effects of exenatide compared with twice-daily biphasic insulin aspart in patients with type 2 diabetes using sulphonylurea and metformin (Abstract)

MA Nauck, S Duran, +3 authors M Trautmann
  • Diabetologia 49:3,
  • 2006
VIEW 1 EXCERPT

Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes.

  • Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
  • 2005

GWAA Study Group: Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes

RJ Heine, LF Van Gaal, +3 authors RG Brodows
  • Ann Intern Med
  • 2005
VIEW 1 EXCERPT